Development asset linked to Kalvista Pharmaceuticals (Ireland) in public FDA and regional records.
pharma · Hereditary Angioedema · Diabetic Macular Edema · KALV
Kalvista Pharmaceuticals (Ireland)
Kalvista Pharmaceuticals (Ireland) Limited
Kalvista Pharmaceuticals (Ireland) drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Framingham, USA HQ
279 Employees
Public company Type
KALV · NYSE Ticker
Company details
- Status
- Public
- HQ
- Framingham, USA
- Employees
- 279
- Programs
- 8
- Drugs
- 6
- Patents
- 24
Kalvista Pharmaceuticals (Ireland) pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kalvista Pharmaceuticals (Ireland) drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Kalvista Pharmaceuticals (Ireland) in public FDA and regional records.
-
Development asset linked to Kalvista Pharmaceuticals (Ireland) in public FDA and regional records.
-
sebetralstat
Blood and blood forming organs (B06)US regulatory status: approved.
-
Development asset linked to Kalvista Pharmaceuticals (Ireland) in public FDA and regional records.